Tesamorelin

Tesamorelin GHRH analog research peptide sourced from verified Chinese manufacturer. 5mg & 10mg vials, purity tested per batch.

Tesamorelin is a growth-hormone-releasing hormone analogue with a specific preclinical niche in visceral-fat research. It is comparatively rare in china peptide catalogs, and rare compounds concentrate sourcing risk: fewer manufacturers make it, and fewer resellers know how to verify it. We coordinate directly with the manufacturer for availability and specification before confirming any tesamorelin order.

Buy Tesamorelin | GHRH Analog | Research Grade | Peptides of China Tesamorelin Buy Tesamorelin — Research Grade GHRH Analog Tesamorelin is a weight management research compound currently in stock directly from a verified Chinese manufacturer. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control. Sourcing is direct — no intermediaries. Public catalog minimum is $300 in goods per supplier. Eligible new customers may use one first-order trial without a monetary minimum; 5% off goods applies from $3,500 per supplier, excluding shipping. International shipping available.

Compound Profile

Tesamorelin is a synthetic analogue of human GHRH consisting of the full 44-amino acid native GHRH sequence conjugated at the N-terminus to trans-3-hexenoic acid. This modification protects the peptide from DPP-IV cleavage at the His²-Ala³ bond — the primary degradation site of native GHRH — while preserving full GHRHR agonist activity. Tesamorelin represents the longest GHRH sequence used as a therapeutic and research compound, contrasting with shorter analogues (sermorelin at 29 AA, CJC-1295 Without DAC at 29 AA with modifications). Its regulatory approval for HIV-associated lipodystrophy-related visceral fat accumulation in 2010 provides an unusually complete translational pharmacology dataset for a research peptide. The primary mechanistic research interest in tesamorelin is the characterisation of sustained, physiologically patterned GH secretion and its metabolic consequences. Unlike CJC-1295 With DAC — which produces sustained supraphysiological GH elevation via albumin binding — tesamorelin’s trans-3-hexenoic acid modification provides moderate DPP-IV protection without albumin binding, resulting in an intermediate pharmacokinetic profile. Clinical studies document significant reductions in visceral adipose tissue (VAT) measured by CT imaging after 26 weeks of administration, with preserved insulin sensitivity compared to exogenous GH. This metabolic selectivity is a central focus of tesamorelin’s research profile. Peptides of China supplies tesamorelin as lyophilized powder at ≥98% purity, verified by HPLC and confirmed by mass spectrometry. Certificates of Analysis available per batch. Wholesale quantities on request. This compound is for laboratory research use only.

Profile

Available Variants

Specification Highlights

Quality & Testing

Testing method: HPLC / LC-MS ([“HPLC”,“LC-MS”,“Water Content”,“Assay”]) . Products are supplied against the specification shown on the applicable product page. The standard catalog purity specification is ≥98% unless otherwise stated. Product-specific specifications and quality-control information may vary by compound and batch. Available documentation: .

**Where provided, these documents reflect the manufacturer’s batch testing for this compound.

Variant Notes

Research material containing tesamorelin.

Research Areas

HIV-Associated Lipodystrophy & Visceral Fat Models The largest body of clinical evidence for tesamorelin addresses HIV-associated lipodystrophy — a metabolic complication of antiretroviral therapy characterised by central visceral fat accumulation with peripheral lipoatrophy. The LIPO-010 and companion phase III trials documented significant reductions in CT-measured visceral adipose tissue (approximately 15–17% over 26 weeks versus placebo) without the hyperglycaemia or IGF-1 overshoot seen with exogenous GH. Preclinical HAART-treated rodent models with lipodystrophy phenotypes use tesamorelin as the positive control in metabolic reversal studies. The selective visceral fat effect is attributed to restoration of physiological GH pulsatility rather than pharmacological GH excess. GH Pulsatility & Somatotroph Function Tesamorelin’s 44-amino acid sequence activates GHRHR with high potency and produces a GH pulse with amplitude and kinetics studied using frequent blood sampling protocols (every 10–20 min). Compared to sermorelin and CJC-1295 Without DAC in comparative pituitary cell and in vivo studies, tesamorelin produces equivalent receptor activation per mole but with moderately extended stability. The compound is used in somatopause research — the age-related decline in GH pulse frequency and amplitude — where restoration of pulsatile GH via GHRHR stimulation is compared with exogenous GH administration for downstream metabolic and body composition endpoints. Cognitive Function & Neurological Research An exploratory strand of tesamorelin research addresses its CNS effects, motivated by GH and IGF-1 receptors’ widespread expression in the brain and the established role of the GH axis in neuronal metabolism. A randomised trial in older adults (TRIUMPHANT-AD) investigated tesamorelin’s effects on cognitive measures and MRI-measured brain structure, noting the relationship between GH axis activity, hippocampal volume, and executive function. Preclinical rat models of age-associated cognitive decline use tesamorelin to characterise GH-dependent neuroplasticity endpoints (BDNF expression, synaptic density) — areas that overlap with the research on GH secretagogues in neurodegeneration. Non-Alcoholic Fatty Liver Disease (NAFLD/MASH) GH deficiency and reduced GH pulsatility are associated with hepatic steatosis. Tesamorelin has been investigated in NAFLD in the context of HIV-associated metabolic disease, with MRI-spectroscopy-measured hepatic fat fraction as the primary endpoint. The proposed mechanism involves GH-stimulated lipolysis in visceral adipose tissue reducing ectopic lipid deposition in the liver, compounded by direct GH receptor-mediated effects on hepatic lipid metabolism. This area connects with the broader research interest in GHRH analogues as metabolic tools in fatty liver models. ## Sourcing Tesamorelin From China

Tesamorelin is available through our platform as a china peptide sourced directly from an established Chinese manufacturer. Three points define how we handle it:

• Factory-direct, not trader-sourced. We confirm availability and specification with the manufacturer before the order is confirmed. There is no intermediary resale of unknown-origin vials in this catalog.
• Specification before shipment. The purity and concentration specification shown on this page is the manufacturer’s batch specification. Product-specific quality-control information travels with the order.
• Research-use discipline. Like every listing in our catalog, Tesamorelin is supplied for laboratory research use only, under strict research-use terms.

For buyers comparing chinese peptides suppliers, the practical test is whether the seller can name the manufacturer and show the batch documentation. We work the other way around: the manufacturer and the documentation are the offer. Browse the full catalog or see how sourcing works.